SynInnova is a knowledge-driven company that has built its business on its unique expertise. Currently, drug discovery research focuses primarily on cost-effectiveness and time. By understanding the needs and pressures of the pharmaceutical industry, we offer a wide range of services to support our customers in their projects of creation, optimization and scale up. At our facility, we can synthesize any challenging target on scales ranging from milligrams to kilograms at competitive prices without compromising quality. Project planning and regular communication are utilized to ensure that customer expectations of quality and delivery are met.
SynInnova is a fully integrated chemistry service provider established to lessen the burden of drug development costs of pharmaceutical and biotech industries. We offer Ph.D. and M.S. level Full Time Equivalent (FTE) scientists who have extensive experience in broad spectrum of chemical synthesis. We gain our customers' trust through our perseverance and strong commitment to quality, confidentiality and timelines.
In general, contract research can be conducted to develop the synthesis of novel compounds, reagents, or new synthetic strategies. At SynInnova, ongoing research focuses on providing new synthetic methodologies, optimizing existing synthetic pathways, and developing specialty reagents to maintain a competitive edge and improve cost efficiency for us and our customers.
We will conduct literature reviews and preliminary studies to evaluate the feasibility of relevant synthetic methods. Upon mutual agreement to proceed with the project, a research agreement must be executed. One or more dedicated chemists will be assigned to the project. The progress of the work will be communicated at regular intervals through written weekly or monthly reports. Samples of intermediate compounds will be available upon request at any stage of the synthesis. Final products will be delivered as per the customers' specifications, and all documentation will be transferred to customers under strict confidentiality.
Cost-effective procedures are playing a major role in research and development within current drug development despite the growing demand for novel drugs in the market. Consequently, there is an increasing need for custom synthesis, which is the core of our business. We alleviate your pressures by creating tailored products at affordable prices. Our highly qualified scientific staff can manage any kind of project prudently within the agreed timelines. With a track record of over 97% success in custom synthesis projects, we guarantee the delivery of products that meet the highest standards of satisfaction. We offer custom synthesis for building blocks, tag molecules, intermediates, small molecules, reference compounds, and novel reagents. Our skilled team excels in various chemistry fields, efficiently creating complex molecules at a low cost. We specialize in aliphatic, aromatic, heterocyclic, boronic acid/ester, carbohydrate, and peptide synthesis to deliver your desired products in required quantities.
Our services include:
In collaboration with SynInnova, we offer design and synthesis of analogs for proprietary scaffolds through our in-house medicinal chemist. We also supply robust building blocks like amines, amides, aldehydes, ketones, halides, esters, acids, alcohols, aromatic scaffolds, boronic acids, steroids, and carbohydrates. Additionally, we source pharmaceutical APIs and bulk intermediates through international contacts.
Over 80% of drug candidates are mostly chiral substances, such as amino acids, carbohydrates, proteins, and nucleic acids. Since the different enantiomers of chiral substances have different physiological activities to the biological targets, it is very important to separate and synthesize pure single enantiomers. A single-configuration chiral molecule is usually a stereoisomer with desired biological activity, but its mirror image molecule is useless or even harmful. Thus, it is necessary to obtain a single chiral enantiomer. By employing state-of-the-art numerous technologies including crystallization resolution, enzymatic resolution, chemical resolution, asymmetric synthesis, HPLC, SFC (supercritical fluid chromatography), as well as a dedicated team of experts SynInnova would be able to provide chiral analysis and separation services in this increasingly complex and high demand area of research.
Peptide therapeutics have shown commercial success since the introduction of insulin therapy in the 1920s. More than 60 peptide drugs are approved in the United States and other major markets, and peptides continue to progress through clinical development at a steady rate. Not surprisingly, the areas of highest concentration for peptide development areas of high interest to the pharmaceutical industry: metabolic disease, oncology, and cardiovascular disease. Research continues to expand the potential range of peptide-based pharmaceuticals to new targets. Over 150 peptides are in active development today.With a dedicated team of experts, SynInnova would be glad to support your peptide-based research.
SynInnova has further expanded its capabilities to include production of stable isotope labelled compounds (SILC). We have an experienced team of scientists to produce stable isotopic labelled compounds in Life Science applications, including biomedical investigations for the development of new drugs. We are excited to offer these SILC products with high quality standards expected in the industry (>98% isotopic and chemical purity) and with competitive prices.
At SynInnova we are working on a wide verity of biologically active compounds, analytical reference standards, drug impurities, metabolites of D, 13C, 15N, and/or 18O. If you cannot find the SILC that you are looking for, then we are happy to provide you a free quote. If you are unsure of the best compound for your research or want to design a compound with the best cost then we can help with that too. Our experience with stable isotope production and with other custom synthesis projects ensures that we can work with you to successfully design and produce a compound to accelerate your Life Science research.
If you need any specific labelled compound(s), please feel free to contact us at sales@syninnova.com.
As the industry is driving towards the cost effectiveness, it is very important to incorporate the best drug characteristics at the earliest possible stage which is achieved by lead optimization. Despite advanced computer modelling programs, the limiting factor is still the generation of high-quality compound libraries. At SynInnova our experienced team of medicinal chemists develop strategies tailored to clients’ needs taking ADME and toxicity issues into consideration to maximize results and minimize the timelines.
We offer the medicinal chemistry services at SynInnova to our customers to design and synthesis of novel compounds against several diseases of our customer's interest.
We provide the following services starting from a validated lead compound usually provided by the customer:
A constant communication with the customer's scientists (project management, chemists, biologists, toxicologists) insures the fast recognition of structure-activity relationships. Using parallel and/or convergent synthesis as well as traditional approaches, our scientists can synthesize quickly a significant variety of compounds.
Even in the early stages we design and synthesize compounds with improved pharmacokinetic (ADME) profiles: increased absorption, modified distribution, modulated sensitivity to metabolism and different elimination kinetics.
SynInnova Laboratories provides end to end CDMO support for pharmaceutical and biotechnology companies, enabling seamless progression from early discovery to clinical and commercial readiness. Our integrated model combines process development, non-GMP manufacturing, and cGMP manufacturing, ensuring that every molecule advances through a scientifically rigorous, safe, and scalable pathway.
Our process development services focus on transforming laboratory chemistry into robust, scalable, and commercially viable manufacturing routes. We support both early stage and clinical stage programs, ensuring each process is efficient, reproducible, and ready for long term deployment.
Capabilities include:
SynInnova provides comprehensive manufacturing solutions across both non-GMP and cGMP environments, enabling smooth progression from early discovery to commercial supply.
Our non-GMP capabilities support early stage research, preclinical development, and rapid material supply. These services offer flexibility, speed, and cost efficiency while maintaining high scientific and operational standards.
Non-GMP Capabilities include:
Non-GMP manufacturing enables fast iteration, quick delivery, and efficient troubleshooting before transitioning into regulated production.
For regulated pharmaceutical applications, SynInnova provides access to FDA approved, globally compliant cGMP facilities through our manufacturing partner in India. These facilities meet international regulatory standards, ensuring quality, consistency, and full documentation for clinical and commercial use.
cGMP Capabilities include:
cGMP manufacturing ensures that every batch meets global regulatory expectations for safety, purity, and reproducibility.
Our reaction capabilities cover a wide range of complex and specialized chemistries required for modern API and intermediate development.
SynInnova’s CDMO model provides a continuous, risk reduced pathway:
This integrated approach shortens timelines, improves reliability, and ensures smooth progression from discovery to market.